PMID- 30619378
OWN - NLM
STAT- MEDLINE
DCOM- 20191119
LR  - 20210108
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 9
DP  - 2018
TI  - Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
PG  - 3059
LID - 10.3389/fimmu.2018.03059 [doi]
LID - 3059
AB  - Dendritic cells (DCs) play a central role in the regulation of the balance 
      between CD8 T cell immunity vs. tolerance to tumor antigens. Cross-priming, a 
      process which DCs activate CD8 T cells by cross-presenting exogenous antigens, 
      plays a critical role in generating anti-tumor CD8 T cell immunity. However, 
      there are compelling evidences now that the tumor microenvironment (TME)-mediated 
      suppression and modulation of tumor-infiltrated DCs (TIDCs) impair their function 
      in initiating potent anti-tumor immunity and even promote tumor progression. 
      Thus, DC-mediated cross-presentation of tumor antigens in tumor-bearing hosts 
      often induces T cell tolerance instead of immunity. As tumor-induced 
      immunosuppression remains one of the major hurdles for cancer immunotherapy, 
      understanding how DCs regulate anti-tumor CD8 T cell immunity in particular 
      within TME has been under intensive investigation. Recent reports on the 
      Batf3-dependent type 1 conventional DCs (cDC1s) in anti-tumor immunity have 
      greatly advanced our understanding on the interplay of DCs and CD8 T cells in the 
      TME, highlighted by the critical role of CD103(+) cDC1s in the cross-priming of 
      tumor antigen-specific CD8 T cells. In this review, we will discuss recent 
      advances in anti-tumor CD8 T cell cross-priming by CD103(+) cDC1s in TME, and 
      share perspective on future directions including therapeutic applications and 
      memory CD8 T cell responses.
FAU - Fu, Chunmei
AU  - Fu C
AD  - Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 
      United States.
FAU - Jiang, Aimin
AU  - Jiang A
AD  - Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 
      United States.
LA  - eng
GR  - P30 CA016056/CA/NCI NIH HHS/United States
GR  - R01 CA198105/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20181220
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (BATF3 protein, human)
RN  - 0 (Basic-Leucine Zipper Transcription Factors)
RN  - 0 (Repressor Proteins)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - Basic-Leucine Zipper Transcription Factors/metabolism
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cell Communication/*immunology
MH  - Cross-Priming/immunology
MH  - Dendritic Cells/*immunology/metabolism
MH  - Humans
MH  - Immunotherapy/methods
MH  - Neoplasms/*immunology/therapy
MH  - Repressor Proteins/metabolism
MH  - Tumor Escape/immunology
MH  - Tumor Microenvironment/*immunology
PMC - PMC6306491
OTO - NOTNLM
OT  - CD103+ cDC1s
OT  - CD8 T cell immunity
OT  - anti-tumor immunity
OT  - cancer immunotherapy
OT  - cross-priming
OT  - tumor microenvironment
EDAT- 2019/01/09 06:00
MHDA- 2019/11/20 06:00
PMCR- 2018/01/01
CRDT- 2019/01/09 06:00
PHST- 2018/09/10 00:00 [received]
PHST- 2018/12/10 00:00 [accepted]
PHST- 2019/01/09 06:00 [entrez]
PHST- 2019/01/09 06:00 [pubmed]
PHST- 2019/11/20 06:00 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2018.03059 [doi]
PST - epublish
SO  - Front Immunol. 2018 Dec 20;9:3059. doi: 10.3389/fimmu.2018.03059. eCollection 
      2018.